As recreational cannabis continues to challenge the status quo in states across the country, mounting research points to the outmodedness of the 1986 U.S. Controlled Substances Act. Mark Kleiman, professor of drug policy at NYU, quickly points out that reforming said legislation is only part of the picture. Reducing the attendant harms of underground markets and their...

Uruguay still has a lot it needs to hash out. Tighter regulations could nudge the price of medicinal cannabis above that of recreational, and a government subsidized cannabis program designed to undercut cartels may prove unsustainable. How Uruguay grapples with these challenges will provide lessons for other states.

This article criticizes the open-endedness of the gateway theory argument as used by cannabis prohibitionists, which explains its very tenacity. Such proponents are often eager to emphasize pharmacological effects in their explanations of cannabis users who acquire harder drugs, but such evidence remains nil, and more evidence-based studies such as those published by the Rand Corporation, or notable academic journals...

The recently released RAND report does much to delineate what we still don’t know about the effects of marijuana, and what questions we need to focus on answering. Gaps remain in our knowledge of its effects on our physiology and because studies capable of drawing conclusive data require time, efforts should be undertaken promptly so...

Drug seizure rates along the US-Mexican border indicate a fall in marijuana imports and a rise in heroin and methamphetamine. Columnist Cory Herro points out that such an increase doesn’t not connote increased consumer uptake in the US; rather Mexican cartel production is outpacing that of  their American counterparts.